<DOC>
	<DOCNO>NCT01997879</DOCNO>
	<brief_summary>The purpose study assess systemic safety absorption AR-13324 healthy volunteer .</brief_summary>
	<brief_title>Study Assessing Ocular Systemic Safety AR-13324 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Healthy adult male female subject least 18 year age . Within 25 % ideal weight . Medically healthy subject clinically insignificant screen result ( laboratory profile , medical history , ECGs , physical exam ) determine Investigator . Nontobacco/nicotine use subject ( minimum 3 month nontobacco/nicotine use prior first dose ) . Subjects two normal ( nondiseased ) eye , define nonclinically significant opinion investigator . Intraocular pressure 14 20 mm Hg ( inclusive ) eye Screening/Qualification . Bestcorrected visual acuity ( BCVA ) eye 20/40 better . Willing able provide write informed consent prior study related procedure comply study requirement . Chronic acute ophthalmic disease include glaucoma , macular degeneration , clinically significant cataract ( primary secondary ) . Previous cataract surgery . Known hypersensitivity component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . Previous glaucoma intraocular surgery glaucoma laser procedure . Refractive surgery ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . Ocular trauma within past six month , ocular surgery laser treatment within past three month ( e.g. , laser treatment glaucoma retina ) . Evidence ocular infection , inflammation , cystoid macular edema , clinically significant blepharitis conjunctivitis ( Screening/ Qualification ) , history herpes simplex keratitis . Ocular medication kind within 30 day Screening/ Qualification Any abnormality prevent reliable applanation tonometry either eye . Central corneal thickness great 600 Âµm . Can demonstrate proper delivery eye drop . Blood donation blood loss , within past 3 month , would put patient risk multiple blood sample require present study . Clinically significant abnormality laboratory test screen . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , cardiovascular endocrine disorder ) might interfere study . Participation investigational study within past 30 day prior screen . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . Due status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use physiciansupervised form birth control least last two month . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine serum pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>